TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00190515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5FU+l-leucovorin
Description: 5FU+l-leucovorin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UFT+Leucovorin
Description: UFT+Leucovorin
Study: NCT00495131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa-2a plus ribavirin
Description: Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (\<75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) for 24 weeks
Study: NCT02046317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Femoral Nerve Block
Description: Femoral Nerve Block for isolated femur fractures

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Femoral Nerve Block
Description: Femoral Nerve Block for isolated femur fractures

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Echogenic needle
Description: The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.
Study: NCT01091181

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hysterotomy at cesarean
Description: incision to open the uterus at cesarean.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hysterotomy at cesarean
Description: incision to open the uterus at cesarean.
Study: NCT01650337

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smartphone Application
Description: Smartphone application to help monitor caloric intake and expenditure
Study: NCT04150835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xingnaojing injection
Description: Xingnaojing injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xingnaojing placebo injection
Description: Xingnaojing placebo injection (20 ml)+0.9% diluted sodium chloride injection 250ml, IV (in the vein), every 12 hours for 10 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Description: Guidelines-based standard care for acute ischemic stroke.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard care
Description: Guidelines-based standard care for acute ischemic stroke.
Study: NCT02477826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study: NCT01323543

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elaspine™
Description: Implantation of device
Study: NCT02477826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study: NCT03347838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a human monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
Study: NCT04057833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E-CEL UVEC
Description: Local implantation of E-CEL UVEC cells at the supraspinatus tendon repair site
Study: NCT02046317

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care needle
Description: The control group will receive ultrasound-guided femoral nerve block using standard of care needles.
Study: NCT03796221

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting videos
Description: Brief online videos, featuring families of children with obesity of diverse backgrounds, to provide education on parenting skills and motivate families to adopt healthy lifestyle behaviors as a family. Videos will be delivered monthly for three months in between pediatric obesity clinic visits.
Study: NCT01737268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK949E
Description: Oral tablet
Study: NCT05547659

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: Pregabalin 150mg preoperative in unimodal group Pregabalin 150mg preoperative in multi-modal group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin 150mg
Description: Pregabalin 150mg preoperative in unimodal group Pregabalin 150mg preoperative in multi-modal group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 1 G Oral Tablet
Description: Acetaminophen 1 G Oral Tablet preoperative in multi-modal group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib 400Mg Oral Capsule
Description: Celecoxib 400Mg Oral Capsule preoperative in multi-modal group
Study: NCT01339221

Intervention type: PROCEDURE
Intervention: Stool samples
Description: Stool samples collected and checked for the presence of rotavirus

Intervention type: PROCEDURE
Intervention: Stool samples
Description: Stool samples collected and checked for the presence of rotavirus
Study: NCT01084421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based parent-adolescent HIV communication
Description: The parental intervention consists of a 60 minute computer-based program delivered in two sessions (one per week). The DVD ROM provides information about adolescent sexual risk and HIV prevention, strategies to support sexual specific communication and parent-adolescent communication in general. The computer based education program is provided in Spanish.
Study: NCT03697460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB018424
Description: INCB018424 PHOSPHATE CREAM 1.5%, topical application, twice daily on lesions of cutaneous LP.
Study: NCT00665561

Intervention type: DRUG
Intervention: Maraviroc along with an optimized background antiretroviral drug regimen
Description: Maraviroc prescribed per approved local label.

Intervention type: DRUG
Intervention: Optimized background antiretroviral drug regimen without maraviroc
Description: Optimized background antiretroviral therapy prescribed per approved local label and treatment guidelines.
Study: NCT00813488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Buccal Tablet
Description: FBT dose strengths = 200, 400, 600, or 800 mcg (1, 2, 3, or 4 tablets) taken prn (as needed) in the event of breakthrough pain.~The maximum dose of FBT permitted during the titration and double-blind periods in this study is 800 mcg (4 tablets).~For the subsequent 12-week open-label treatment period, patients will either continue with FBT treatment or begin treatment with an alternative short-acting opioid deemed appropriate for each patient by the clinician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Buccal Tablet
Description: FBT dose strengths = 200, 400, 600, or 800 mcg (1, 2, 3, or 4 tablets) taken prn (as needed) in the event of breakthrough pain.~The maximum dose of FBT permitted during the titration and double-blind periods in this study is 800 mcg (4 tablets).~For the subsequent 12-week open-label treatment period, patients will either continue with FBT treatment or begin treatment with an alternative short-acting opioid deemed appropriate for each patient by the clinician.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate release oxycodone
Description: Immediate release oxycodone dosage strength: 15, 30, 45, and 60 mg doses (1, 2, 3 or 4 capsules) to be taken prn (as needed) for breakthrough pain.~The maximum single dose would be 60 mg (4 capsules).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate release oxycodone
Description: Immediate release oxycodone dosage strength: 15, 30, 45, and 60 mg doses (1, 2, 3 or 4 capsules) to be taken prn (as needed) for breakthrough pain.~The maximum single dose would be 60 mg (4 capsules).
Study: NCT01273090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imetelstat sodium

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Study: NCT00425542

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Outpatient care (vs traditional inpatient care)
Description: Patients randomized to the outpatient arm are discharged from the emergency department within 24 hours after randomization. Patients randomized to the inpatient arm are admitted to the hospital and are discharged based on the decision of the managing physician at the hospital.
Study: NCT03677375

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00026
Description: Noninvasive pulse oximeter sensor
Study: NCT00901056

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal Shockwave Therapy
Description: Energy Density - 0.02 - 0.15 mJ/mm2
Study: NCT04145102

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hesperidine
Description: used for antibacterial and reminerlization assesment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: propolis
Description: used for antibacterial and reminerlization assesment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: silver diamine fluoride
Description: used for antibacterial and reminerlization assesment
Study: NCT04463953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib,Ixazomib and Dexamethasone
Description: Zanubrutinib, 160mg orally, twice a day; Ixazomib, 4 mg orally, day 1, 8, 15; Dexamethasone, 20mg orally, days 1, 8, 15；Ixazomib and dexamethasone every 4 weeks of a cycle, with induction of 6 cycles, and then maintain every 12 weeks, up to 6 cycles (96 cycles in total). Zanubrutinib is taken orally twice a day for up to 96 cycles, with a reduction in the last ID cycle. ZID regimen will continue 6 cycles after reaching the maximum response after introduction section.
Study: NCT03796221

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard pediatric obesity treatment
Description: Standard treatment in a hospital-based pediatric obesity clinic with a team of medical providers, dietitians, exercise specialists, and behavioral health specialists. Treatment includes management of obesity-related medical conditions, nutrition education, physical activity counseling, and discussion of behavioral strategies such as goal-setting and self-monitoring, with elements of motivational interviewing used to encourage behavior change and adoption of healthy lifestyle behaviors by the entire family.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard pediatric obesity treatment
Description: Standard treatment in a hospital-based pediatric obesity clinic with a team of medical providers, dietitians, exercise specialists, and behavioral health specialists. Treatment includes management of obesity-related medical conditions, nutrition education, physical activity counseling, and discussion of behavioral strategies such as goal-setting and self-monitoring, with elements of motivational interviewing used to encourage behavior change and adoption of healthy lifestyle behaviors by the entire family.
Study: NCT04439357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib Dimethyl Sulfoxide
Description: Given PO
Study: NCT03829683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: 200mg/kg/24hours
Study: NCT02046317

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.~The control group will receive ultrasound-guided femoral nerve block using standard of care needles.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: The experimental arm will receive ultrasound-guided femoral nerve block using echogenic needles, which are micro laser etched near the tip to reflect sound waves back to the transducer and make the tip visible.~The control group will receive ultrasound-guided femoral nerve block using standard of care needles.
Study: NCT04364763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBT-9 (90 mg)
Description: Subjects will receive a single dose and study duration will be approximately 60 days per subject.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride (normal saline)
Description: Subjects will receive a single dose and study duration will be approximately 60 days per subject.
Study: NCT04609397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005
Description: Hemay005 tables 60mg bid p.o;

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hemay005
Description: Hemay005 tables 60mg bid p.o;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemay005
Description: Hemay005 tables 45mg bid p.o

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hemay005
Description: Hemay005 tables 45mg bid p.o

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo to Hemay005 tables bid p.o
Study: NCT04498676

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CB-0002B
Description: CB-0002B (choline geranate) is a viscous transparent colorless to light yellow liquid
Study: NCT02455947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inquiry Based Stress Reduction (IBSR)
Description: During a 12-week intervention program, participants will be encouraged to identify and inquire their stressful thoughts.All the sessions were standardized according to a training manual, and were assessed after each session for maintaining consistency in the program.
Study: NCT04432077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DINO Strategies for Anxiety and fear of Uncertainty Reduction (DINOSAUR)
Description: DINO Strategies for Anxiety and fear of Uncertainty Reduction (DINOSAUR) - a parent-mediated cognitive-behavioral treatment modified for young children with ASD
Study: NCT00748137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ezy-BICC dose calculation card
Description: small laminated table lists the dose of insulin to administer based on BGL and carbohydrate to be consumed - individualised for each study subject

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fixed dose
Description: Approach where study subject is prescribed a set amount of carbohydrate to eat each meal and set dose of rapid acting insulin. Minor modifications may be made if the measured BGL is out of target
Study: NCT01176981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Methotrexate
Description: Methotrexate will be given by IV at a dose of 12 gram/m2/dose.~The patient will receive 4-6 hours of hydration with alkalinization, and then HD MTX will be infused over 4 hours. Following this, the patient will be discharged home to receive continuous intravenous hydration through a portable pump. The patient will return to hospital daily for a comprehensive clinical assessment, IV hydration and antiemetics, MTX level and creatinine monitoring until MTX is cleared (3-4 days).
Study: NCT01316432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenderitide
Description: Cenderitide is a novel rationally designed chimeric natriuretic peptide to be administered in this trial as either a subcutaneous injection or infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenderitide
Description: Cenderitide is a novel rationally designed chimeric natriuretic peptide to be administered in this trial as either a subcutaneous injection or infusion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a 24-hour SQ infusion
Study: NCT03969108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: ICG is a fluorescent dye which binds tightly to plasma proteins and becomes confined to the vascular system.
Study: NCT00834314

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vacuum-Pack-technique for temporary abdominal closure
Description: Negative-pressure-wound-therapy applying a method described by Brock, Barker et al 1995: Temporary Closure of Open Abdominal Wounds - the Vacuum Pack (see citations).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal-dressing-technique for temporary abdominal closure
Description: Negative-pressure-wound-therapy for temporary abdominal closure applying a device of KCI International (V.A.C.® Abdominal Dressing System). see: http://www.kci-medical.com/kci/corporate/kcitherapies/vactherapy/dressings/abdominal/#
Study: NCT04361838

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: prayer
Description: receive prayers daily while in ICU
Study: NCT00494741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Patients randomized in this group will receive 750 mg of MMF per os twice a day starting on the day of transplant. MMF dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azathioprine
Description: Patients randomized in this group will receive 75 mg of AZA per os (or 125 mg if body weight \> 75 kg) once a day starting on the day of transplant. AZA dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.
Study: NCT00876265

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belotero
Description: Belotero, injectable hyaluronic acid gel device, implanted into the nasolabial fold in the Treatment Phase of the study (multiple injections of 0.1 to 0.2 mL, up to a maximum of 3 mL over 2 treatment sessions). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zyplast
Description: Zyplast Collagen Implant, an injectable dermal collagen device, implanted into the nasolabial fold in the Treatment Phase of the study (average injection of 1.0 mL). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered. Zyplast was obtained by each site from commercially available supplies.
Study: NCT02134275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whole body vibration training
Description: Each whole body vibration session will consist of a 20 min timed stand on the vibration platform where participants will stand with their knees in a slightly flexed position (120°) while the plate oscillates. The vibration frequency will be set at ranges between 20-40Hz and the amplitude set at 2mm displacement.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Participants in this group will be asked to not make any significant changes to their lifestyle behaviors, such as diet and exercise, for the duration of the study.
Study: NCT05040737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PS membrane versus PMMA membrane,
Description: Patients will be dialysed according to the usual dialysis schedule of three weekly sessions. The study has a duration of 8 days in order to include 4 haemodialysis sessions. The first and third haemodialysis sessions will be dialysed with PS membrane and the second and fourth sessions with PMMA membrane, both dialysers with a surface area of 1.8 m2.
Study: NCT00616993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Difluprednate
Description: Difluprednate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle
Study: NCT01173536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0449
Description: Oral repeating dose
Study: NCT00495131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated interferon alfa-2a plus ribavirin
Description: Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (\<75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) for 48 weeks
Study: NCT01041729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Patients with Peripheral Arterial Disease in Fontaine Stage II treated with Atorvastatin 40mg/day during 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Patients with Peripheral Arterial Disease in Fontaine Stage II without treatment with Atorvastatin 40mg/day during 12 months.~Standard Medical Treatment.
Study: NCT02034422

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Antioxidant
Description: Consisting of vitamins C, E and alpha lipoic acid.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Antioxidant
Description: Consisting of vitamins C, E and alpha lipoic acid.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise rehabilitation
Description: 8 weeks of exercise rehabilitation
Study: NCT02847468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FDG Positron Emission Tomography
Description: Subject will performed Positrons Emission tomography (PET) with 18F-Fluorocholine (FDG) before treatment with Sorafenib is started and 1 month after treatment started.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FCH Positron Emission Tomography
Description: Subject will performed Positrons Emission tomography (PET) with 18F-Fluorocholine (FCH) before treatment with Sorafenib is started and 1 month after treatment started.